Literature review demonstrates hormonal and psychosocial impacts on sexual health in women with PCOS, suggesting the need for better management.
Introduction Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder affecting women of childbearing age, defined by hyperandrogenism, ovulatory dysfunction, and metabolic disorders. Besides its reproductive and metabolic effects, PCOS is also related to sexual dysfunction in different domains, including desire, arousal, lubrication, orgasm, satisfaction, and pain. Sexual dysfunction in PCOS is still not well recognized and poorly managed despite its high prevalence.c Objective The primary objective is to understand the impact of PCOS on sexual health, reviewing how the syndrome affects sexual function, including desire, arousal, and satisfaction, and to learn about the various hormonal, metabolic, and psychosocial factors that contribute to sexual dysfunction in women with PCOS. Methods This research examines existing literature about sexual dysfunction in PCOS. The Female Sexual Function Index (FSFI) served as the main instrument to evaluate sexual function. The review specifically examined research analyzing hormonal profiles together with BMI and insulin resistance, and psychosocial factors, to determine links between metabolic disturbances and sexual dysfunction in this population. Results The literature consistently reveals that women with PCOS obtain lower FSFI scores than controls, particularly in the domains of desire, arousal, orgasm, and satisfaction. However, one study revealed an unexpected outcome: hyperandrogenism showed positive effects on desire but adverse effects on total sexual satisfaction, highlighting a complex and domain-specific relationship between hormones and sexual function. Conclusions Sexual dysfunction is a prevalent and frequently overlooked comorbidity in women with PCOS. While hyperandrogenism may positively influence sexual desire, its overall impact on satisfaction and quality of life remains negative. It is imperative that clinicians utilize validated instruments, such as the FSFI, to screen for this dysfunction and enhance the quality of life of the affected women through comprehensive and tailored management strategies. Disclosure No
No takes yet. Share an insight, caveat, or question.
Ibanez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: